Adoptive immunotherapy for Hodgkin's lymphoma.
Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved. In this article, we discuss the promise of Epstein-Barr virus-specific cytotoxic T-lymphocytes, the roles of cytokines, and other strategies for overcoming the immune-evasion mechanisms in Hodgkin's lymphoma.
Kennedy-Nasser
Alana A
AA
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA.
Bollard
Catherine M
CM
Rooney
Cliona M
CM
D016207:Cytokines / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D006689:Hodgkin Disease / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*; D019139:Tumor Escape / Q000276:immunology*
D016207:Cytokines